Cell-Free Systems Explained: The PURE System for Protein Synthesis

Cell-free protein synthesis enables rapid prototyping of biosynthetic pathways by manufacturing individual enzymes in vitro, allowing researchers to mix and match enzyme combinations to study pathway performance, optimize enzyme ratios and cofactor concentrations, and identify optimal enzyme homologs. This approach reduces the design-build-test cycle from weeks to approximately one day, enabling the testing of thousands of pathway combinations and achieving significant improvements in product yields (e.g., three-fold increase in butanol production) through systematic optimization using machine learning and the Tree Score ranking system.

This video presents an integrated approach combining CRISPR-based in vivo metabolic engineering with cell-free biosynthesis for rapid prototyping of genes and pathways. The method uses tiled guide RNA libraries synthesized at JGI to systematically tune gene expression levels across entire metabolic networks, identifying optimal expression levels (not just maximum overexpression or knockout) that improve pathway performance. Rewired cells are then lysed to create enhanced cell-free extracts that enable faster reaction kinetics, higher productivities, and greater flexibility in reaction conditions compared to living cells. This bidirectional workflow allows researchers to discover beneficial genetic modifications in vivo and immediately test them in vitro, accelerating the design-build-test cycle for metabolic engineering.

Cell-free transcription-translation (TXTL) systems enable protein synthesis outside living cells by providing purified cellular machinery including transcription and translation components, ATP regeneration systems, amino acids, and cofactors. The workflow involves preparing DNA templates and mixing them with reaction components, then incubating for several hours to produce proteins. TXTL enables three main applications: prototyping gene circuits and pathways, biomanufacturing proteins and viral particles, and creating synthetic cells. Advanced applications include synthesizing complete viral genomes (up to 289 genes for T4 phage), engineering phage genomes through in vitro assembly and selection, and developing synthetic cells using liquid-liquid phase separation or liposome encapsulation. Microfluidic chips enable spatial organization of gene circuits for studying pattern formation and communication between neighboring cells. This technology accelerates genetic circuit design, enables rapid prototyping of CRISPR components, and provides a platform for exploring synthetic biology without requiring living host cells.

Cell-free protein synthesis uses cell lysates containing transcription/translation machinery combined with energy solutions and DNA templates to produce proteins outside living cells. The E. coli lysate system includes cytoplasmic components, ribosomes, and enzymes. Preparation involves growing cells to exponential phase, sonicating to break membranes, centrifuging to remove debris, and performing runoff reactions to finish ongoing translations. Advantages include rapid turnaround (8-hour reactions), no GMO concerns, high parallelization in multi-well plates, precise composition control, and compatibility with linear DNA. Applications range from historical genetic code research to modern synthetic biology prototyping, phage production, and antibody manufacturing.

Acoustic liquid handling systems like the Labcyte Echo enable rapid, high-throughput prototyping of cell-free transcription-translation (TXTL) reactions by reducing reaction volumes to 2 microliters and accelerating setup times 5-10 times compared to manual pipetting, making it ideal for characterizing genetic circuits and CRISPR technologies in synthetic biology research.

The site-specific incorporation of unnatural amino acids into proteins in live cells was demonstrated by Schultz and coworkers in the early 2000s, achieved by identifying orthogonal tRNA-synthetase pairs from different organisms (particularly archaea) that can be engineered to incorporate non-natural amino acids without interfering with the native genetic code; this methodology involves selecting tRNAs that decode stop codons and synthetases that specifically recognize unnatural amino acids, followed by iterative protein engineering using combinatorial saturation mutagenesis and genetic selection to optimize orthogonality, enabling the incorporation of over 30 different unnatural amino acids as of 2006.

Genetic code expansion allows incorporation of non-canonical amino acids using orthogonal tRNA/tRNA synthetase pairs. The process requires a non-canonical amino acid that enters cells and resists metabolism, a unique codon recognized by the orthogonal tRNA, and an orthogonal synthetase pair. The Phe stop codon is commonly repurposed, and the pyrrolysyl-tRNA synthetase system from archaea provides a versatile orthogonal pair. Over 200 distinct non-canonical amino acids have been installed using this strategy, enabling access to catalytic chemistries beyond nature's repertoire.

This section covers the design and characterization of orthogonal ribosomes for expanding the genetic code. The Ribo-X ribosome was engineered with two mutations to improve suppression of amber stop codons by tRNA over termination by release factor one. Three experimental approaches were used: (1) GST-MBP fusion proteins with radio-labeled cysteine probes showed error frequencies below 1 in 10^3 for cysteine incorporation; (2) Comparative efficiency testing with benzophenone (BPA) as the unnatural amino acid demonstrated that Ribo-X achieved 64% suppression efficiency with one unnatural amino acid versus 24% with the Schultz method, and 22% versus 1% with two unnatural amino acids. These results demonstrate that orthogonal ribosome design can minimize truncated peptide phenotypes caused by release factor competition, enabling more reliable unnatural amino acid incorporation for chemical biology applications.

Orthogonal translation systems require modifying three components: tRNA synthetase (to charge non-canonical amino acids), tRNA (to recognize orthogonal synthetase), and EF-Tu (to accept non-standard amino acids). The biggest challenge is developing orthogonal synthetases. Common systems include pyrrolysine synthetase from Methanopyrus kandleri. Stop codons can be reassigned as initiation codons for N-terminal modifications. EF-Tu engineering with six mutations enables non-canonical amino acid incorporation. Chemical methods using radical chemistry can modify proteins post-translationally, achieving configurations matching natural modifications.

Amber suppression enables incorporation of unnatural amino acids into proteins by exploiting the amber stop codon (UAG). The technique requires three components: a plasmid encoding the protein of interest with a UAG substitution at the desired position, a plasmid encoding orthogonal tRNA and aminoacyl-tRNA synthetase pairs that recognize only the unnatural amino acid, and the unnatural amino acid itself supplied during expression. This approach works in living cells, is bio-orthogonal to native cellular chemistry, and functions effectively even in the presence of cysteines. Applications include installing post-translational modifications (phosphorylated serine, acetylated lysine), fluorescent probes, EPR probes, and bio-orthogonal handles (norbornene, cyclooctynes) for targeted conjugation. Practical considerations include optimizing expression conditions, managing truncation products, avoiding isotope scrambling during C-13 labeling, and confirming incorporation via mass spectrometry.

mRNA display is a powerful in vitro selection technique that enables scientists to discover proteins with high affinity for specific targets by linking mRNA to nascent peptides through puromycin during translation, then performing reverse transcription to cDNA, affinity chromatography to select binding proteins, and PCR amplification to iteratively enrich for optimal protein candidates; unlike phage display which is limited to 1-10 billion amino acids, mRNA display can generate proteins up to 10^15 amino acids in length, making it particularly valuable for pharmaceutical and medical applications where longer, more sophisticated proteins may offer better therapeutic efficacy.

mRNA display links proteins directly to their encoding mRNA templates through puromycin incorporation, enabling high-throughput screening of protein libraries. Modified puromycin with flexible linkers attaches to mRNA ends, creating covalent protein-mRNA conjugates during in vitro translation. Researchers can select proteins with desired properties by isolating conjugated mRNA and sequencing it, enabling directed evolution and combinatorial library screening. This technique differs from ribosome display, which keeps proteins attached to ribosome-mRNA complexes. mRNA display provides a powerful platform for discovering novel proteins with specific binding properties or catalytic activities.

Ribosome display is an in vitro cell-free technology for selecting and evolving proteins by physically linking protein phenotypes to their corresponding mRNA genotypes in stable PRM (protein-RNA-ribosome) complexes, enabling high-throughput screening of protein libraries for antibody ligands, binding peptides, and functional proteins through iterative selection rounds combined with PCR amplification; this method offers advantages over cell-based approaches including unlimited library diversity and convenient integration of mutagenesis strategies, with applications ranging from antibody discovery to non-antibody protein selection across prokaryotic, eukaryotic, and ribosome inactivation display systems.

In vitro selection is a powerful experimental technique developed in the 1990s for isolating functional RNA, DNA, and proteins. The method involves creating large libraries of random sequences (10^15 variants), subjecting them to selective pressures that enrich for molecules performing desired functions, and then amplifying survivors through cycles of selection and amplification. This Darwinian-like process allows discovery of functional molecules that would be extremely difficult to find through traditional methods. The technique has been applied to understand how much information is required to specify functional molecules, revealing that achieving higher function requires approximately 10 additional bits per tenfold increase in activity.

Directed evolution methods have been essential for developing functionalized flagellin-based biosensors. Ribosome display was initially used but found to be too large relative to the proteins, causing non-specific binding that interfered with selection. The click display method was developed as an alternative, where complementary DNA is synthesized from RNA and covalently linked to the synthesized protein. This approach allows selection of proteins that maintain polymerization capability while acquiring desired functions. The method has been used to select fluorescent proteins and binding proteins that serve as alternatives to antibodies for fluorescent protein detection.

DARPA initiated a program to develop on-demand therapeutic manufacturing for forward-deployed medical providers, requiring: generic platform capable of producing diverse protein therapeutics, portability allowing production within 24 hours, complete end-to-end manufacturing chain including purification, and production of FDA-approved biologics with consistency matching hospital-grade injectables. Cell-based systems were deemed impractical due to minimum 24-hour timelines. Conventional manufacturing involves complex multi-stage processes: master cell bank storage, cell expansion through multiple stages, large-scale reactor cultivation, recovery/purification steps, stabilization, formulation, and shipping. The proposed paradigm shift moves manufacturing to the point of care using compact modular systems. Cell-free IVT systems eliminate living cells and cold chain requirements, enabling raw materials to be stored lyophilized and reconstituted on demand. Early studies produced FDA-approved therapeutics like arthropoietin at single-band purity in less than two days, and streptokinase with high potency. Producing single-dose biologics requires manufacturing conditions with precision comparable to electronics manufacturing. Generic purification strategies use inteins—self-cleaving polypeptide sequences that respond to pH or temperature switches to release pure tagless protein.

Cell-free protein expression is a powerful biotechnology that extracts cellular machinery (transcription and translation enzymes) from living cells to synthesize proteins in vitro, offering advantages over traditional cell-based methods including faster workflow, elimination of transformation steps, and the ability to produce toxic or difficult-to-express proteins; this technology has three main applications: protein production for research and therapeutics, functional genomics studies to understand biological systems, and point-of-care diagnostics where freeze-dried cell-free systems can be embedded in paper or pellets for portable, decentralized healthcare applications.

Cell-free biosensing uses lysed bacterial extracts containing transcription and translation machinery to detect biomarkers. This platform addresses limitations of traditional clinical testing by enabling finger-stick blood collection, low-cost assays (pennies per test), and deployment in resource-limited settings without electricity or specialized equipment. Polymer-based two-phase systems (dextran/PEG) enable compartmentalization of reactions into separate droplets, allowing simultaneous detection of nucleic acids, proteins, and small molecules from the same sample. Freeze-dried colorimetric reporters (X-gal/lacZ) provide visually interpretable readouts suitable for point-of-care applications.

This comprehensive section presents the transformative shift from traditional living cell systems to revolutionary freeze-dried cell-free platforms. Cell-free extracts are created by breaking open cells and removing all maintenance factors, leaving only active translational machinery capable of performing transcription and translation when provided with DNA/RNA templates. The freeze-drying process removes 99.9% of water, creating lightweight, shelf-stable powders functional for up to one year. Key advantages include on-demand activation by adding water, rapid protein production (1-2 hours), high efficiency (~1g/L), enhanced biocontainment, simplicity, room temperature operation, and complete cold chain elimination. Applications span point-of-care diagnostics (Ebola, Zika sensors developed in 5 days) and distributed biomanufacturing (15 antibodies, violacein biosynthesis, antimicrobial peptides, and protein vaccines). Parallel developments democratize science through BioBits kits bringing synthetic biology to high school classrooms, and wearable biosensor technology integrating cell-free systems into textiles for continuous health monitoring.

Cell-free systems enable three major applications: (1) Cell-free metabolism produces biofuels and chemicals by combining native E. coli enzymes with custom DNA-encoded enzymes; (2) Biosensors use transcription factors to detect environmental contaminants (antibiotics, toxins, heavy metals) with concentration-dependent signals; (3) Glycoengineering adds sugar groups to proteins (antibodies, vaccines) to enhance stability and immune recognition. Each application leverages the same core technology—mixing cell extract with DNA instructions to produce functional biological systems outside living cells.